{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:20:47Z","timestamp":1788675647629,"version":"build-2803163510"},"reference-count":48,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hidradenitis Suppurativa (HS) is a chronic, recurrent, inflammatory, follicular skin disease whose pathology is complex and not fully understood. The objective of this study was to elucidate the role of IL\u201017A in moderate\u2010to\u2010severe HS. Transcriptomic and histological analyses were conducted on ex vivo HS (<jats:italic>n<\/jats:italic>\u00a0=\u200919; lesional and non\u2010lesional) and healthy control (<jats:italic>n<\/jats:italic>\u00a0=\u20098) skin biopsies. Further, a Phase II exploratory, randomized, double\u2010blind, placebo\u2010controlled study was carried out in moderate\u2010to\u2010severe HS patients. Patients were treated with either CJM112 300\u2009mg (<jats:italic>n<\/jats:italic>\u00a0=\u200933), a fully human anti\u2010IL\u201017A IgG1\/\u03ba monoclonal antibody, or placebo (<jats:italic>n<\/jats:italic>\u00a0=\u200933). The main outcome of the translational analyses was to identify IL\u201017A\u2010producing cells and indications of IL\u201017A activity in HS lesional skin. The primary objective of the clinical study was to determine the efficacy of CJM112 in moderate\u2010to\u2010severe HS patients by HS\u2010Physician Global Assessment (HS\u2010PGA) responder rate at Week 16. Transcriptomic and histopathologic analyses revealed the presence of heterogeneous cell types in HS lesional skin; IL\u201017A gene signatures were increased in HS lesional vs non\u2010lesional or healthy skin. High expression of IL\u201017A was localized to T cells, neutrophils, and mast cells, confirming the transcriptional data. Clinically, the proportion of Week 16 HS\u2010PGA responders was significantly higher (<jats:italic>p<\/jats:italic>\u00a0=\u20090.03) in the CJM112 group vs placebo (32.3% vs 12.5%). This study elucidated the role of the IL\u201017A pathway in HS pathogenesis and clinically validated the IL\u201017A pathway in moderate\u2010to\u2010severe HS patients in a proof\u2010of\u2010concept study using the anti\u2010IL\u201017A\u2010specific antibody CJM112.<\/jats:p>","DOI":"10.1111\/exd.14619","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T10:44:12Z","timestamp":1653993852000},"page":"1522-1532","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["<scp>IL\u201017A<\/scp> is a pertinent therapeutic target for moderate\u2010to\u2010severe hidradenitis suppurativa: Combined results from a pre\u2010clinical and phase <scp>II<\/scp> proof\u2010of\u2010concept study"],"prefix":"10.1111","volume":"31","author":[{"given":"Alexa B.","family":"Kimball","sequence":"first","affiliation":[{"name":"Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Loesche","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Errol P.","family":"Prens","sequence":"additional","affiliation":[{"name":"Department of Dermatology Erasmus University Medical Centre  Rotterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk G.","family":"Bechara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology Ruhr\u2010University Bochum  Bochum Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Weisman","sequence":"additional","affiliation":[{"name":"Advanced Medical Research  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Rozenberg","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Jarvis","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Peters","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Roth","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazyna","family":"Wieczorek","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kolbinger","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor B. E.","family":"Jemec","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zeeland University Hospital, Roskilde, Health Sciences Faculty University of Copenhagen  Roskilde Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.16691"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000443878"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000507348"},{"issue":"6","key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2340\/0001555576482483","article-title":"A case\u2010control study of hidradenitis suppurativa in an STD population","volume":"76","author":"Jemec GB","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.020"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.255"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14038"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1301"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18707"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.5070\/D3236035391"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00068"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-020-01381-7"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.04.011"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13449"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.033"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0141"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.010"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.042"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15769"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2794"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.005"},{"issue":"6","key":"e_1_2_9_24_1","first-page":"788","article-title":"Ixekizumab in hidradenitis suppurativa: a case report in a psoriatic patient","volume":"155","author":"Odorici G","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13756"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19478"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.007"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14792"},{"key":"e_1_2_9_29_1","unstructured":"JemecGBE SayedC SchmiederG et al.Efficacy and safety of bimekizumab a dual interleukin (IL)\u201017A and IL\u201017F inhibitor for the treatment of moderate\u2010to\u2010severe hidradenitis suppurativa (HS): a 12\u2010week randomised double\u2010blind placebo\u2010controlled phase 2 study. Paper presented at: 9th Conference of European Hidradenitis Suppurativa Foundation 2020; 5\u20137 February 2020 Athens Greece."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17071"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-12-201212180-00004"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130301"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627139"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419858963"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2450401"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1596-5"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14214"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14075"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.04.036"},{"key":"e_1_2_9_42_1","first-page":"733","article-title":"Serum concentration and skin expression of S100A7 (Psoriasin) in patients suffering from hidradenitis suppurativa","volume":"1","author":"Batycka\u2010Baran A","year":"2020","journal-title":"Dermatology"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2012.24.4.393"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10034.x"},{"issue":"10","key":"e_1_2_9_45_1","first-page":"1192","article-title":"Adalimumab treatment in women with moderate\u2010to\u2010severe hidradenitis suppurativa from the placebo\u2010controlled portion of a phase 2, randomized, double\u2010blind study","volume":"15","author":"Gottlieb A","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.065"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00439-5"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17822"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.14619","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/exd.14619","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.14619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T07:24:06Z","timestamp":1692602646000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.14619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/exd.14619"],"URL":"https:\/\/doi.org\/10.1111\/exd.14619","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"2022-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}